title: Comparison of antihyperglycemic effects of creatine and glibenclamide in type II diabetic patients.
abstract: This study compares the effects of glibenclamide and creatine in type II diabetics. In a 14-day symmetrically randomized crossover trial recently detected type II diabetics received either creatine (3 g) or glibenclamide (3.5 mg) for five successive days, followed by two days of washout, and crossover to the opposite treatment. Glucose, insulin, c-peptide, and creatine were measured. Creatine and glibenclamide decreased glucose concentrations vs. basal glucose [-15, 60, 90, 120, 180, and 240 min; mol/l]: 12.6±0.83 vs. 12.2±0.56 vs. 12.1±0.57, 15.3±0.63 vs. 13.5± 0.70(a ) vs. 13.0±0.57(a), 14.8±0.57 vs. 13.8±0.59(a) vs. 13.4±0.46(a), 14.6±0.61 vs. 12.3±0.49(b) vs. 12.4±0.61(a), 12.8±0.76 vs. 10.0± 0.40(c) vs. 10.3±0.41(c), and 11.4±0.67 vs. 8.3±0.40(c) vs. 8.5±0.36(c); ((a) p<0.05; (b) p<0.01; (c) p<0.001 vs. basal glucose). Treatment with both creatine and glibenclamide increased insulin and c-peptide concentrations after 120 and 240 min (p<0.05 and p<0.01). At the doses applied short-term treatment with creatine and glibenclamide elicits similar glucose lowering effects.
authors.affiliation: Vuk Vrhovac University Clinic for Diabetes, Merkur Clinical Hospital Zagreb, University of Zagreb, Zagreb, Croatia. rocic@idb.hr
authors.forename: Boris
authors.initials: B
authors.lastname: Ročić
authors.forename: Ariana
authors.initials: A
authors.lastname: Znaor
authors.forename: Petra
authors.initials: P
authors.lastname: Ročić
authors.forename: David
authors.initials: D
authors.lastname: Weber
authors.forename: Marijana
authors.initials: M
authors.lastname: Vučić Lovrenčić
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000097:blood; D003401:Creatine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005905:Glyburide / Q000009:adverse effects / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D006943:Hyperglycemia / Q000097:blood / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D019518:Postprandial Period
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D003401:Creatine; D005905:Glyburide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; C517652:hemoglobin A1c protein, human